- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05070013
Adaptive Neurostimulation to Restore Sleep in Parkinson's Disease (Aim 2)
Adaptive Neurostimulation to Restore Sleep in Parkinson's Disease: An Investigation of STN LFP Biomarkers in Sleep Dysregulation and Repair
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
In our previous work, we investigated the use of local field potentials (LFP) recorded from STN-DBS electrodes to identify unique spectral patterns in STN oscillatory activity that correlate with distinct sleep cycles, offering insight into sleep dysregulation and supporting the notion that biomarkers from STN-recorded LFP could be used to identify specific sleep stages. Aim 1 of this study, ClinicalTrials.gov ID: NCT04620551, characterized the relationship between aberrant STN activity (via LFP) and sleep dysregulation in PD by recording and analyzing three consecutive nights of STN-LFP with concurrent PSG. During the third night we collected sleep recordings as we delivered sub-threshold stimulation, to assess how stimulation affects sleep-stage duration and transitions. These data directly informed the development and optimization of an adaptive stimulation algorithm.
The current study will assess the efficacy of the adaptive stimulation algorithm and will test the working hypothesis that modulation of STN during nighttime sleep will normalize sleep behavior by offsetting aberrant signaling in the sleep network. Investigators will use subjective assessments, 3-week actigraphy, and nocturnal PSG, in 20 PD subjects 3 months after DBS implantation, a point at which DBS and medication will have been therapeutically optimized for PD motor symptoms. Investigators will compare chronic open-loop stimulation to adaptive stimulation, and to a no-stimulation control group. All subjects will experience each of the 3 conditions (one condition per week; OFF-Stim, ON-Stim-Adaptive, ON-Stim-Open), however the order in which each subject is assigned to a condition will be randomized while preserving a balanced ratio of group assignments. Investigators will monitor sleep architecture and quality in all groups for 3 weeks prior to DBS surgery, and then at 3 months post-DBS surgery, using in-home actigraphy. Subjects will be blinded with respect to group assignment to mitigate subject bias, which will be set by the Research Host PC when a subject initiates the recording sequence.
The rationale for this aim is (1) to validate a therapeutic intervention for the burdensome non-motor symptom of sleep dysfunction in PD, and (2) to fill a critical gap in our understanding of the contribution of STN-DBS to ameliorating sleep-wake disturbances in PD. The acquisition of these data will improve the understanding of the role of basal ganglia, specifically STN, in sleep hemostasis in PD. We expect that STN-DBS will improve sleep-wake parameters in both the PSG and actigraphy recordings but that adaptive stimulation, targeted at sleep-stage biomarkers, will further optimize sleep and alleviate this non-motor burden in PD. Specifically, we predict that adaptive more so than chronic open-loop STN-DBS during sleep will decrease nonconsolidated sleep, reduce the frequency of awakenings, increase the percentage time spent in REM sleep, reduce daytime sleepiness, and increase subjective experience of restfulness and sleep quality.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Dulce Maroni, PhD
- Phone Number: 402-836-9751
- Email: dmaroni@unmc.edu
Study Locations
-
-
Nebraska
-
Omaha, Nebraska, United States, 68198
- Recruiting
- University of Nebraska Medical Center
-
Contact:
- Dulce Maroni, PhD
- Phone Number: 402-836-9751
- Email: dmaroni@unmc.edu
-
Principal Investigator:
- Aviva Abosch, MD, PhD
-
Contact:
- Andrew Schnaubelt, PhD
- Phone Number: 402-559-4846
- Email: andy.schnaubelt@unmc.edu
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19106
- Recruiting
- University of Pennsylvania Health System
-
Contact:
- Marie Kerr, CCRP
- Phone Number: 215-829-6720
- Email: marie.kerr@pennmedicine.upenn.edu
-
Principal Investigator:
- Casey Halpern, MD
-
Contact:
- NIda Firdous, MD
- Phone Number: 215-829-6720
- Email: nida.firdous@pennmedicine.upenn.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Ability to provide informed consent for this study.
- Signed informed consent.
- Diagnosis of Idiopathic Parkinsons disease with motor symptoms that have been present for a minimum of 4 years.
- Motor symptoms (e.g., motor fluctuations, dyskinesia, tremor, bradykinesia, rigidity) that are severe enough, despite optimized medical therapy, to warrant surgical implantation of DBS, according to standard clinical criteria.
- UPDRS-III score off medication between 20 and 80, and an improvement in UPDRS-III score on medications of at least 30%, or patients with tremor-dominant PD (score >/= 2 on UPDRS-III tremor sub-score) or tremor in addition to other motor symptoms that are treatment-resistant and result in significant functional disability.
- Appropriate trials of oral PD medications have resulted in inadequate relief of motor symptoms as determined by a movement disorders neurologist, and anti-PD medications have been at stable doses for 30 days prior to study enrollment.
- Patient has requested DBS surgery, and has been approved by the site (UNMC or University of Pennsylvania) Multi-Disciplinary Movement Disorders Patient Care Conference for STN DBS
- Absence of abnormalities on brain MRI suggestive of an alternate diagnosis or serving as a contraindication to surgery.
- Absence of significant cognitive deficits or significant depression (BDI-II score > 20) on formal Neuropsychological Testing.
- Age 18 to 80 years (19 years for Nebraska)
- Ability to conduct follow up neurological care exclusively at the study site for the duration of the RC+S INS lifespan (9 years).
Exclusion Criteria:
- Coagulopathy, anticoagulant medications that cannot be discontinued safely for perioperative period, uncontrolled hypertension, history of seizures, heart disease, inability to undergo general anesthesia, or other medical conditions considered to place the patient at elevated risk for surgical complications.
- Pregnancy: All women of child-bearing age will have a negative urine pregnancy test prior to undergoing surgical procedures.
- Significant untreated depression (BDI-II score > 20 or GDS score > 8).
- Personality or mood disorder symptoms that Study Personnel believe will interfere with study requirements
- Patients requiring ongoing treatment with ECT, rTMS, or diathermy.
- Pre-existing implanted stimulation system (e.g., cochlear implant, cardiac pacemaker, defibrillator, neuro-stimulator for indication other than Parkinsons disease) or ferromagnetic metallic implant.
- Prior intracranial surgery.
- History of, or active, drug or alcohol abuse.
- Meets criteria for PD with Mild Cognitive Impairment (PD-MCI), as defined by Performance > 2 standard deviations below appropriate norms on tests from 2 or more of the following cognitive domains: Attention, Executive Function, Language, Memory, and Visuospatial Ability.
- Patients with Restless Leg Syndrome.
- Patients with Obstructive Sleep Apnea.
- Inability to perform the recharge process necessary for use of the RC+S system.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Adaptive DBS stimulation
Subjects experience adaptive stimulation during one week of at-home night sleep.
|
All subjects will undergo three 1-week conditions of stimulation during nighttime sleep over the course of three consecutive weeks of in-home sleep: adaptive stimulation, open-loop stimulation and no stimulation.
|
Active Comparator: Open-loop DBS stimulation
Subjects experience open-loop stimulation (standard clinical stimulation therapy based on DBS programming for the treatment of motor symptoms) during one week of at-home night sleep.
|
All subjects will undergo three 1-week conditions of stimulation during nighttime sleep over the course of three consecutive weeks of in-home sleep: adaptive stimulation, open-loop stimulation and no stimulation.
|
No Intervention: No DBS Stimulation
DBS stimulation is turned off (control) during one week of at-home night sleep.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Sleep efficiency
Time Frame: Years 1-3
|
Sleep fragmentation frequency and duration will be measured using FDA-approved wrist-based Actigraphy (ActiWatch Spectrum Pro).
|
Years 1-3
|
Subjective Sleep Quality
Time Frame: Years 1-3
|
Change in subjective sleep quality will be measured between the 3 stimulation conditions.
The measure will be captured using the Pittsburgh Sleep Diary.
|
Years 1-3
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Duration of REM sleep stage
Time Frame: Years 1-3
|
Change in the duration of REM stage sleep will be measured between the 3 stimulation conditions.
We will use the artificial neural network to identify sleep stage and assess whether the duration changes as a function of stimulation protocol.
|
Years 1-3
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Aviva Abosch, MD, PhD, University of Nebraska
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 0577-21-FB
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson's Disease
-
Ohio State UniversityCompletedParkinson's Disease | Parkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease | Parkinson Disease, Idiopathic | Parkinson's Disease, IdiopathicUnited States
-
Assistance Publique - Hôpitaux de ParisFrance Parkinson AssociationUnknownHealthy Controls | Parkinson's Disease With LRRK2 Mutation | Parkinson's Disease Without LRRK2 MutationFrance
-
Merck Sharp & Dohme LLCCompletedParkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease
-
Universidade Federal de PernambucoCompletedParkinson's Disease.Brazil
-
University Hospital, GrenobleCompletedParkinson's Disease (Disorder)France
-
Shanghai East HospitalShanghai iCELL Biotechnology Co., Ltd, Shanghai, ChinaRecruitingIdiopathic Parkinson's DiseaseChina
-
Beijing Tiantan HospitalRecruitingPD - Parkinson's DiseaseChina
-
AbbVieActive, not recruitingParkinson's Disease (PD)United States, Australia
-
AbbVieCompletedParkinson's Disease (PD)United States, Australia
-
BlueRock TherapeuticsMemorial Sloan Kettering Cancer CenterActive, not recruitingAdvanced Parkinson's DiseaseUnited States, Canada
Clinical Trials on Deep Brain Stimulation
-
Abbott Medical DevicesTerminatedDepressive Disorder, Major | Unipolar DepressionUnited States, Canada, United Kingdom
-
Zhiqi MaoRecruitingParkinson's Disease | Executive Function | Electroencephalogram | Functional Near - Infrared SpectroscopyChina
-
Ali Rezai, MDCompleted
-
University Hospital Inselspital, BerneCompletedMovement Disorder | Urinary Tract DiseaseSwitzerland
-
University of MinnesotaRecruitingParkinson DiseaseUnited States
-
NewronikaTerminatedParkinson DiseaseItaly
-
Butler HospitalMedtronicCompletedObsessive-Compulsive DisorderUnited States
-
University of Sao Paulo General HospitalUnknownCerebellar AtaxiaBrazil
-
Boston Scientific CorporationCompletedParkinson's DiseaseUnited States
-
Qilu Hospital of Shandong UniversityRecruiting